id: NEW:psychosocial_intervention_for_aud_to_substance_use_treatment_dropout_rate
name: Psychosocial Intervention for Alcohol Use Disorder â†’ Substance Use Treatment Dropout Rate
from_node:
  node_id: NEW:psychosocial_intervention_for_aud
  node_name: Psychosocial Intervention for Alcohol Use Disorder
to_node:
  node_id: substance_use_treatment_dropout_rate
  node_name: Substance Use Treatment Dropout Rate
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Individuals with AUD are enrolled in psychosocial intervention programs'
- 'Step 2: Treatment discontinuation rates are measured as indicator of treatment acceptability and feasibility'
- 'Step 3: No significant difference in treatment discontinuation between intervention and control groups'
evidence:
  quality_rating: A
  n_studies: 13
  primary_citation: 'Abhishek Ghosh et al. 2024. "Effectiveness of psychosocial interventions for alcohol
    use disorder: a systematic review and meta-analysis update." https://doi.org/10.1080/00952990.2024.2350056'
  supporting_citations:
  - Additional citations require full-text access - studies from meta-analysis examining treatment discontinuation
  - Studies included in WHO Mental Health Gap Action Programme guideline update
  doi: 10.1080/00952990.2024.2350056
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: 'Psychosocial interventions for AUD do not significantly affect treatment discontinuation
  rates compared to treatment-as-usual (RR = 1.09, 95% CI: 0.66 to 1.80), suggesting comparable acceptability
  and tolerability'
quantitative_effects:
  effect_size:
    value: 1.09
    type: relative_risk
    ci_lower: 0.66
    ci_upper: 1.8
  sample_size: 2575
structural_competency:
  equity_implications: Similar treatment retention across intervention and control groups suggests that
    psychosocial interventions are not more burdensome than standard care. However, structural factors
    affecting treatment access and retention (transportation, work schedules, childcare, stigma) are not
    captured in these clinical trials. Addressing these structural barriers is essential for translating
    trial efficacy into real-world effectiveness, particularly for marginalized populations who face compounded
    access barriers.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.251458'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
